<p>Supplementary Material, Supplementary_files_final_version_PREFERMS for Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial by Bruce A.C. Cree, Douglas L. Arnold, Mark Cascione, Edward J. Fox, Ian M. Williams, Xiangyi Meng, Lesley Schofield and Nadia Tenenbaum in Therapeutic Advances in Neurological Disorders</p
Supplemental material, MSJ795332_supplementary_figure_3 for Effects and mechanisms of differently cu...
Supplemental material, sj-docx-1-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, MSJ794063_supplementary_material for Over three decades study populations in ...
Supplemental material for Real-world experience of fingolimod in patients with multiple sclerosis (M...
Supplemental material, Supplementary_File_1 for Post-natalizumab disease reactivation in multiple sc...
ObjectiveIn relapsing-remitting multiple sclerosis (RRMS), suboptimal adherence to injectable diseas...
Supplemental material, Supplementary_File_2 for Post-natalizumab disease reactivation in multiple sc...
Supplemental material, sj-docx-3-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, MSJ795332_supplementary_file_1 for Effects and mechanisms of differently cued...
Objective: In relapsing–remitting multiple sclerosis (RRMS), suboptimal adherence to injectable dise...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-2-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189674 for Intermediate outcomes for clinica...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, MSJ795332_supplementary_table_2 for Effects and mechanisms of differently cue...
Supplemental material, MSJ795332_supplementary_figure_3 for Effects and mechanisms of differently cu...
Supplemental material, sj-docx-1-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, MSJ794063_supplementary_material for Over three decades study populations in ...
Supplemental material for Real-world experience of fingolimod in patients with multiple sclerosis (M...
Supplemental material, Supplementary_File_1 for Post-natalizumab disease reactivation in multiple sc...
ObjectiveIn relapsing-remitting multiple sclerosis (RRMS), suboptimal adherence to injectable diseas...
Supplemental material, Supplementary_File_2 for Post-natalizumab disease reactivation in multiple sc...
Supplemental material, sj-docx-3-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, MSJ795332_supplementary_file_1 for Effects and mechanisms of differently cued...
Objective: In relapsing–remitting multiple sclerosis (RRMS), suboptimal adherence to injectable dise...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-2-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189674 for Intermediate outcomes for clinica...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, MSJ795332_supplementary_table_2 for Effects and mechanisms of differently cue...
Supplemental material, MSJ795332_supplementary_figure_3 for Effects and mechanisms of differently cu...
Supplemental material, sj-docx-1-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, MSJ794063_supplementary_material for Over three decades study populations in ...